Dalargin

Phase 3Small molecule

BBotkin Hospital

Dalargin is one of 5 small molecule programs targeting Abdominal Surgery. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Abdominal SurgeryActive, not recruiting

Abdominal SurgeryPhase 3

Active, not recruiting

Competition

Competitive Landscape

4 competitors in Abdominal Surgery

#DrugCompanyPhaseTrials

Ketalar

AAultman Health Foundation

Phase 3

4 2

Xylocaine

MMEDRx USA, Inc.

Phase 3

3 3

Cyklokapron

JJ Molner

Phase 3

1 4

Dalargin

BBotkin Hospital

Phase 3

1 5

Lidocaine and Ketamine

TThe Cleveland Clinic

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 3Active, not recruiting

Abdominal Surgery

NCT07404358

Clinical

Trials by Indication[1]

Abdominal Surgery1 trial

Dalargin for Prevention of Organ Disfunction in High-Risk Abdominal Surgery

Active, not recruiting·—·Phase 3·NCT07404358·200 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Dalargin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Dalargin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Dalargin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Botkin Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: BBotkin Hospital

Dalargin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Abdominal Surgery1 trial

References

Drug Info

Quick Facts

Related News